Efficacy of Zofenopril Compared with Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies
| Autor: | Giorgio Reggiardo, Stefano Omboni, Daniela Degli Esposti, Claudio Borghi, Ettore Ambrosioni, Stefano Bacchelli |
|---|---|
| Přispěvatelé: | DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Facolta' di MEDICINA e CHIRURGIA, AREA MIN. 06 - Scienze mediche, Borghi, Claudio, Omboni, Stefano, Reggiardo, Giorgio, Bacchelli, Stefano, Esposti, Daniela Degli, Ambrosioni, Ettore |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Ramipril
Male cardiovascular risk medicine.medical_specialty Captopril Myocardial Infarction Angiotensin-Converting Enzyme Inhibitors Acute myocardial infarction 030204 cardiovascular system & hematology Placebo 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Risk Factors Internal medicine Medicine Humans 030212 general & internal medicine Myocardial infarction Prospective Studies Risk factor Aged Randomized Controlled Trials as Topic Retrospective Studies angiotensinconverting enzyme inhibitors Pharmacology business.industry Hazard ratio Lisinopril Middle Aged medicine.disease Zofenopril drug therapy Cardiology and Cardiovascular Medicine Treatment Outcome chemistry Cardiovascular Diseases Cardiology Original Article Female Myocardial infarction diagnosis business angiotensinconverting enzyme inhibitor medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology |
| Popis: | none 6 no In the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 1, 3, and 4 studies, early administration of zofenopril in acute myocardial infarction showed to be prognostically beneficial versus placebo or ramipril. The SMILE-2 showed that both zofenopril and lisinopril are safe and showed no significant differences in the incidence of major cardiovascular (CV) complications. In this pooled analysis of individual data of the SMILE studies, we evaluated whether the superior efficacy of zofenopril is maintained also in patients with 1 CV risk factor (CV+, n = 2962) as compared to CV2 (n = 668). The primary study end point was set to 1-year combined occurrence of death or hospitalization for CV causes. The risk of CV events was significantly reduced with zofenopril versus placebo either in the CV+ (237%; hazard ratio: 0.63; 95% confidence interval: 0.51-0.78; P = 0.0001) or in the CV2 group (255%; hazard ratio: 0.45; 0.26-0.78; P = 0.004). Also, the other angiotensinconverting enzyme inhibitors reduced the risk of major CV outcomes, though the reduction was not statistically significant versus placebo (CV+: 0.78; 0.58-1.05; P = 0.107; CV2: 0.71; 0.36-1.41; P = 0.334). The benefit was larger in patients treated with zofenopril than other angiotensin-converting enzyme inhibitors, with a statistically significant difference for CV+ (0.79; 0.63-0.99; P = 0.039) versus CV2 (0.62; 0.37-1.06; P = 0.081). In conclusion, zofenopril administered to patients after acute myocardial infarction has a positive impact on prognosis, regardless of the patient's CV risk profile. none Borghi, Claudio; Omboni, Stefano; Reggiardo, Giorgio; Bacchelli, Stefano; Esposti, Daniela Degli; Ambrosioni, Ettore Borghi, Claudio; Omboni, Stefano; Reggiardo, Giorgio; Bacchelli, Stefano; Esposti, Daniela Degli; Ambrosioni, Ettore |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|